The manufacturing of pharmaceutical proteins is a multi-disciplinary feat that translates molecular biology into life-saving medicine through a rigorous process of "biomanufacturing". While early therapeutics like insulin were once laboriously extracted from animal organs, modern biotechnology utilizes genetically engineered "living factories"—such as bacteria, yeast, or mammalian cells—to produce human-compatible proteins at a massive scale. The Blueprint: From Gene to Cell Bank
The journey begins at the genetic level. Scientists identify the specific DNA sequence that codes for a therapeutic protein and "clone" it into a vector. This vector is inserted into a host cell, such as E. coli or Chinese Hamster Ovary (CHO) cells, effectively giving the cell the instructions to build the protein. Once a high-performing cell line is identified, it is preserved in a "master cell bank" to ensure long-term consistency for every future batch. Upstream Processing: Cultivating the Product
Upstream processing focuses on growing these engineered cells to high densities to maximize protein yield.
Manufacturing of Pharmaceutical Proteins - Wiley Online Library
